{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T21:13:02Z","timestamp":1774645982652,"version":"3.50.1"},"reference-count":59,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2006,12,1]],"date-time":"2006-12-01T00:00:00Z","timestamp":1164931200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Best Practice & Research Clinical Haematology"],"published-print":{"date-parts":[[2006,12]]},"DOI":"10.1016\/j.beha.2006.05.002","type":"journal-article","created":{"date-parts":[[2006,9,23]],"date-time":"2006-09-23T11:29:43Z","timestamp":1159010983000},"page":"655-668","source":"Crossref","is-referenced-by-count":33,"title":["Radioimmunotherapy for B-cell non-Hodgkin lymphoma"],"prefix":"10.1016","volume":"19","author":[{"given":"Thomas E.","family":"Witzig","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.beha.2006.05.002_bib1","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1200\/JCO.1998.16.8.2825","article-title":"Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program","volume":"16","author":"McLaughlin","year":"1998","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.beha.2006.05.002_bib2","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1200\/JCO.2005.12.052","article-title":"Rituximab therapy for patients with newly diagnosed, advanced-stage, follicular grade I non-Hodgkin's lymphoma: a phase II trial in the North Central Cancer Treatment Group","volume":"23","author":"Witzig","year":"2005","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.beha.2006.05.002_bib3","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1182\/blood.V97.1.101","article-title":"Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation","volume":"97","author":"Colombat","year":"2001","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.beha.2006.05.002_bib4","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1182\/blood.V106.11.349.349","article-title":"Maintenance rituximab after CVP results in superior clinical outcome in advanced follicular lymphoma: results of the E1496 phase III trial from the Eastern Cooperative Oncology Group and the Cancer and Leukemia Group B","volume":"106","author":"Hochster","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.beha.2006.05.002_bib5","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1182\/blood-2004-08-3175","article-title":"CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma","volume":"105","author":"Marcus","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.beha.2006.05.002_bib6","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V106.11.353.353","article-title":"Chimeric anti-CD20 monoclonal antibody (Rituximab;Mabthera) in remission induction and maintenance treatment of relapsed\/resistant follicular non-Hodgkin's lymphoma: final analysis of a phase III randomized intergroup clinical trial","volume":"106","author":"Van Oers","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.beha.2006.05.002_bib7","doi-asserted-by":"crossref","first-page":"4279","DOI":"10.1182\/blood-2002-11-3442","article-title":"Rituximab plus CHOP (R-CHOP) overcomes bcl-2\u2013associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL)","volume":"101","author":"Mounier","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.beha.2006.05.002_bib8","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJMoa011795","article-title":"CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma","volume":"346","author":"Coiffier","year":"2002","journal-title":"The New England Journal of Medicine"},{"issue":"19","key":"10.1016\/j.beha.2006.05.002_bib9","doi-asserted-by":"crossref","first-page":"3121","DOI":"10.1200\/JCO.2005.05.1003","article-title":"Rituximab-CHOP vs CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lympoma","volume":"24","author":"Habermann","year":"2006","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.beha.2006.05.002_bib10","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1269\/jrr.46.241","article-title":"Pretreatment with rituximab enhances radiosensitivity of non-Hodgkin's lymphoma cells","volume":"46","author":"Skvortsova","year":"2005","journal-title":"Journal of Radiation Research"},{"key":"10.1016\/j.beha.2006.05.002_bib11","doi-asserted-by":"crossref","first-page":"3545","DOI":"10.1200\/JCO.2002.02.126","article-title":"Radiolabeled anti-CD20 monoclonal antibodies for the treatment of B-cell lymphoma","volume":"20","author":"Dillman","year":"2002","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.beha.2006.05.002_bib12","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1182\/blood-2002-06-1793","article-title":"Radioimmunotherapy of non-Hodgkin lymphomas","volume":"101","author":"Cheson","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.beha.2006.05.002_bib13","doi-asserted-by":"crossref","first-page":"8447","DOI":"10.1200\/JCO.2005.03.1674","article-title":"New treatment options have changed the survival of patients with follicular lymphoma","volume":"23","author":"Fisher","year":"2005","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.beha.2006.05.002_bib14","first-page":"465","article-title":"Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: combined data from 4 clinical trials","volume":"44","author":"Wiseman","year":"2003","journal-title":"Journal of Nuclear Medicine"},{"key":"10.1016\/j.beha.2006.05.002_bib15","doi-asserted-by":"crossref","first-page":"3793","DOI":"10.1200\/JCO.1999.17.12.3793","article-title":"Phase I\/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma","volume":"17","author":"Witzig","year":"1999","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.beha.2006.05.002_bib16","first-page":"21S","article-title":"Iodine-131 anti-B1 antibody for B-cell lymphoma: an update on the Michigan Phase I experience","volume":"39","author":"Wahl","year":"1998","journal-title":"Journal of Nuclear Medicine"},{"key":"10.1016\/j.beha.2006.05.002_bib17","first-page":"14S","article-title":"Patient-specific whole-body dosimetry: principles and a simplified method for clinical implementation","volume":"39","author":"Wahl","year":"1998","journal-title":"Journal of Nuclear Medicine"},{"key":"10.1016\/j.beha.2006.05.002_bib18","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1056\/NEJM199308123290703","article-title":"Radioimmunotherapy of B-cell lymphoma with [131I]anti-B1 (anti-CD20) antibody","volume":"329","author":"Kaminski","year":"1993","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.beha.2006.05.002_bib19","first-page":"1S","article-title":"Iodine-131 anti-B1 antibody therapy in non-Hodgkin's lymphoma: dosimetry and clinical implications","volume":"39","author":"Wahl","year":"1998","journal-title":"Journal of Nuclear Medicine"},{"key":"10.1016\/j.beha.2006.05.002_bib20","first-page":"457","article-title":"Update on hybrid conjugate-view SPECT tumor dosimetry and response in 131I-tositumomab therapy of previously untreated lymphoma patients","volume":"44","author":"Koral","year":"2003","journal-title":"Journal of Nuclear Medicine"},{"key":"10.1016\/j.beha.2006.05.002_bib21","first-page":"457","article-title":"Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma","volume":"2","author":"Knox","year":"1996","journal-title":"Clinical Cancer Research"},{"key":"10.1016\/j.beha.2006.05.002_bib22","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1200\/JCO.1996.14.7.1974","article-title":"Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma","volume":"14","author":"Kaminski","year":"1996","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.beha.2006.05.002_bib23","first-page":"39a","article-title":"Phase I\/II study of iodine-131 anti-B1 antibody for non-Hodgkin's lymphoma (NHL): final results","volume":"17","author":"Stagg","year":"1998","journal-title":"Proceedings of the American Society of Clinical Oncology"},{"key":"10.1016\/j.beha.2006.05.002_bib24","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1200\/JCO.2003.08.043","article-title":"Safety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-hodgkin's lymphoma","volume":"21","author":"Witzig","year":"2003","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.beha.2006.05.002_bib25","first-page":"287a","article-title":"Patient-specific dosing of Bexxar\u2122 is associated with tolerable and predictable hematologic toxicity in patients with known hematologic risk factors","volume":"20","author":"Fehrenbacher","year":"2001","journal-title":"Proceedings of the American Society of Clinical Oncology"},{"key":"10.1016\/j.beha.2006.05.002_bib26","doi-asserted-by":"crossref","first-page":"4336","DOI":"10.1182\/blood.V99.12.4336","article-title":"Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial","volume":"99","author":"Wiseman","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.beha.2006.05.002_bib27","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1200\/JCO.2000.18.6.1316","article-title":"Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed\/refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphomas","volume":"18","author":"Vose","year":"2000","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.beha.2006.05.002_bib28","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1056\/NEJMoa041511","article-title":"131I-tositumomab therapy as initial treatment for follicular lymphoma","volume":"352","author":"Kaminski","year":"2005","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.beha.2006.05.002_bib29","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.1200\/JCO.2001.19.19.3918","article-title":"Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas","volume":"19","author":"Kaminski","year":"2001","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.beha.2006.05.002_bib30","doi-asserted-by":"crossref","first-page":"4576","DOI":"10.1182\/blood-2004-12-4690","article-title":"Assessment of treatment-related myelodysplastic syndromes and acute myeloid leukemia in patients with non-Hodgkin lymphoma treated with tositumomab and iodine I131 tositumomab","volume":"105","author":"Bennett","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.beha.2006.05.002_bib31","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1200\/JCO.1986.4.10.1470","article-title":"Follicular lymphoma: prognostic factors for response and survival","volume":"4","author":"Gallagher","year":"1986","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.beha.2006.05.002_bib32","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1200\/JCO.2002.11.076","article-title":"Randomized controlled trial of 90Y-labeled ibritumomab tiuxetan (zevalin) radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed b-cell non-Hodgkin's lymphoma","volume":"20","author":"Witzig","year":"2002","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.beha.2006.05.002_bib33","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1200\/JCO.1999.17.4.1244","article-title":"Report of an international workshop to standardize response criteria for non-Hodgkin's lymphoma","volume":"17","author":"Cheson","year":"1999","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.beha.2006.05.002_bib34","doi-asserted-by":"crossref","first-page":"7792","DOI":"10.1158\/1078-0432.CCR-04-0756","article-title":"The radioisotope contributes significantly to the activity of radioimmunotherapy","volume":"10","author":"Davis","year":"2004","journal-title":"Clinical Cancer Research"},{"key":"10.1016\/j.beha.2006.05.002_bib35","doi-asserted-by":"crossref","first-page":"3262","DOI":"10.1200\/JCO.2002.11.017","article-title":"Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma","volume":"20","author":"Witzig","year":"2002","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.beha.2006.05.002_bib36","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1200\/JCO.2005.07.040","article-title":"Efficacy and safety of tositumomab and iodine-131 tositumomab (Bexxar) in B-cell lymphoma, progressive after rituximab","volume":"23","author":"Horning","year":"2005","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.beha.2006.05.002_bib37","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1089\/cbr.2005.20.185","article-title":"Yttrium-90 (90Y) ibritumomab tiuxetan (Zevalin) induces long-term durable responses in patients with relapsed or refractory B-Cell non-Hodgkin's lymphoma","volume":"20","author":"Wiseman","year":"2005","journal-title":"Cancer Biotherapy & Radiopharmaceuticals"},{"key":"10.1016\/j.beha.2006.05.002_bib38","doi-asserted-by":"crossref","first-page":"7565","DOI":"10.1200\/JCO.2004.00.9217","article-title":"Tositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-Hodgkin's lymphomas","volume":"23","author":"Fisher","year":"2005","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.beha.2006.05.002_bib39","doi-asserted-by":"crossref","first-page":"4429","DOI":"10.1182\/blood-2003-11-3883","article-title":"Durable responses after ibritumomab tiuxetan radioimmunotherapy for CD20+ B-cell lymphoma: long-term follow-up of a phase 1\/2 study","volume":"103","author":"Gordon","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.beha.2006.05.002_bib40","article-title":"Yttrium-90 ibritumomab tiuxetan (Zevalin) for patients with relapsed\/refractory diffuse large B-cell lymphoma not appropriate for autologous stem cell transplantation: results of an open-label phase II trial","volume":"110","author":"Morschhauser","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.beha.2006.05.002_bib41","article-title":"Patients with transformed low grade lymphoma attain durable responses following outpatient radioimmunotherapy with tositumomab and iodine I 131 tositumomab [Bexxar\u00ae]","volume":"100","author":"Zelenetz","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.beha.2006.05.002_bib42","doi-asserted-by":"crossref","first-page":"2632","DOI":"10.1182\/blood.V104.11.2632.2632","article-title":"A phase II study of yttrium 90 (90Y) ibritumomab tiuxetan (Zevalin\u00ae) for treatment of patients with relapsed and refractory mantle cell lymphoma (MCL)","volume":"104","author":"Oki","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.beha.2006.05.002_bib43","doi-asserted-by":"crossref","first-page":"3885","DOI":"10.1200\/JCO.2002.10.143","article-title":"Subsequent chemotherapy regimens are well tolerated after radioimmunotherapy with yttrium-90 ibritumomab tiuxetan for non-Hodgkin's lymphoma","volume":"20","author":"Ansell","year":"2002","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.beha.2006.05.002_bib44","doi-asserted-by":"crossref","first-page":"202","DOI":"10.3816\/CLM.2004.n.028","article-title":"Antilymphoma treatments given subsequent to yttrium 90 ibritumomab tiuxetan are feasible in patients with progressive non-Hodgkin's lymphoma: a review of the literature","volume":"5","author":"Ansell","year":"2004","journal-title":"Clinical Lymphoma"},{"key":"10.1016\/j.beha.2006.05.002_bib45","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1038\/sj.bmt.1703398","article-title":"Successful autologous peripheral blood stem cell transplantation in transformed follicular lymphoma previously treated with radioimmunotherapy (iodine (131)I tositumomab)","volume":"29","author":"Cooney","year":"2002","journal-title":"Bone Marrow Transplantation"},{"key":"10.1016\/j.beha.2006.05.002_bib46","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1002\/cncr.21606","article-title":"Subsequent therapy can be administered after tositumomab and iodine I-131 tositumomab for non-Hodgkin lymphoma","volume":"106","author":"Dosik","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.beha.2006.05.002_bib47","doi-asserted-by":"crossref","first-page":"7985","DOI":"10.1200\/JCO.2005.01.0892","article-title":"Re-treatment with I-131 tositumomab in patients with non-Hodgkin's lymphoma who had previously responded to I-131 tositumomab","volume":"23","author":"Kaminski","year":"2005","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.beha.2006.05.002_bib48","first-page":"358a","article-title":"Yttrium-90 Zevalin phase I sequential dose radioimmunotherapy trial of patients with relapsed low grade and follicular B-cell non-Hodgkins lymphoma (NHL): preliminary results","volume":"100","author":"Wiseman","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.beha.2006.05.002_bib49","first-page":"358a","article-title":"Yttrium-90 Zevalin phase I sequential dose radioimmunotherapy trial of patients with relapsed low grade and follicular B-cell non-Hodgkins lymphoma (NHL): preliminary results","volume":"100","author":"Wiseman","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.beha.2006.05.002_bib50","doi-asserted-by":"crossref","first-page":"5696","DOI":"10.1200\/JCO.2005.14.803","article-title":"Abbreviated chemotherapy with fludarabine followed by tositumomab and iodine I 131 tositumomab for untreated follicular lymphoma","volume":"23","author":"Leonard","year":"2005","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.beha.2006.05.002_bib51","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1056\/NEJM199310213291702","article-title":"Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support","volume":"329","author":"Press","year":"1993","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.beha.2006.05.002_bib52","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/S0140-6736(95)92225-3","article-title":"Phase II trial of 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas","volume":"346","author":"Press","year":"1995","journal-title":"Lancet"},{"key":"10.1016\/j.beha.2006.05.002_bib53","doi-asserted-by":"crossref","first-page":"3270","DOI":"10.1200\/JCO.1998.16.10.3270","article-title":"Follow-up of relapsed B-cell lymphoma patients treated with iodine-131-labeled anti-CD20 antibody and autologous stem-cell rescue","volume":"16","author":"Liu","year":"1998","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.beha.2006.05.002_bib54","doi-asserted-by":"crossref","first-page":"2934","DOI":"10.1182\/blood.V96.9.2934","article-title":"A phase I\/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas","volume":"96","author":"Press","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.beha.2006.05.002_bib55","doi-asserted-by":"crossref","first-page":"3158","DOI":"10.1182\/blood.V99.9.3158","article-title":"High-dose chemo-radioimmunotherapy with autologous stem cell support for relapsed mantle cell lymphoma","volume":"99","author":"Gopal","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.beha.2006.05.002_bib56","doi-asserted-by":"crossref","first-page":"2896","DOI":"10.1182\/blood-2005-03-1310","article-title":"A phase 1\/2 trial of high-dose yttrium-90-ibritumomab tiuxetan in combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell transplantation in patients with poor-risk or relapsed non-Hodgkin lymphoma","volume":"106","author":"Nademanee","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.beha.2006.05.002_bib57","doi-asserted-by":"crossref","first-page":"S22","DOI":"10.3816\/CLM.2004.s.005","article-title":"Combining yttrium 90-labeled ibritumomab tiuxetan with high-dose chemotherapy and stem cell support in patients with relapsed non-Hodgkin's lymphoma","volume":"5","author":"Winter","year":"2004","journal-title":"Clincal Lymphoma"},{"key":"10.1016\/j.beha.2006.05.002_bib58","first-page":"411a","article-title":"Zevalin dose-escalation followed by high-dose BEAM and autologous peripheral blood progenitor cell (PBPC) transplant in non-Hodgkin's lymphoma: early outcome results","volume":"100","author":"Winter","year":"2002","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.beha.2006.05.002_bib59","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1002\/cncr.21998","article-title":"Safety and efficacy of external beam radiation therapy for non-Hodgkin lymphoma in patients with prior 90Y-ibritumomab tiuxetan radioimmunotherapy","volume":"107","author":"Justice","year":"2006","journal-title":"Cancer"}],"container-title":["Best Practice & Research Clinical Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692606000338?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692606000338?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T14:21:39Z","timestamp":1627827699000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521692606000338"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,12]]},"references-count":59,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2006,12]]}},"alternative-id":["S1521692606000338"],"URL":"https:\/\/doi.org\/10.1016\/j.beha.2006.05.002","relation":{},"ISSN":["1521-6926"],"issn-type":[{"value":"1521-6926","type":"print"}],"subject":[],"published":{"date-parts":[[2006,12]]}}}